Neutralizing antibodies against LIF have driven TAMs to acquire antitumor and proinflammatory functions, and combining anti-LIF with anti-PD1 results in a strong antitumor response in colon cancer, GBM, and ovarian cancer [20,25]. Here, LIF is linked to colonic neoplasm.